Simulations Plus Inc
NASDAQ:SLP
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Simulations Plus Inc
NASDAQ:SLP
|
237.7m USD |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
29.8B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
13.2B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
4.7B USD |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.5B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
36.2B SEK |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
24.5B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
270.8B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Simulations Plus Inc is 59.6%, which is below its 3-year median of 67.9%.
Over the last 3 years, Simulations Plus Inc’s Gross Margin has decreased from 79.9% to 59.6%. During this period, it reached a low of 53.7% on May 31, 2025 and a high of 80.7% on Feb 28, 2023.
